Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Lymphoma, T-Cell, Cutaneous 2Vascular Malformations 1Surgical Wound Infection 1Pancreatic Neoplasms 1Pain 1Mycosis Fungoides 1Keratosis, Actinic 1High-grade Anal Intraepithelial Neoplasia 1Hemangioma, Capillary 1Hemangioma 1Head and Neck Neoplasms 1Dermatitis, Contact 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Lymphedema 1

Interventions

Carboplatin 330Pemetrexed 266Cisplatin 234Docetaxel 195Paclitaxel 182Radiotherapy 181Erlotinib Hydrochloride 153pembrolizumab 147Gemcitabine 147Bevacizumab 125Drug Therapy 121Radiosurgery 115Nivolumab 112osimertinib 92durvalumab 88Gefitinib 67atezolizumab 63Vinorelbine 63Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 54anlotinib 42Immunotherapy 42Taxes 39Blood Specimen Collection 39Ipilimumab 38130-nm albumin-bound paclitaxel 38Specimen Handling 36Immune Checkpoint Inhibitors 35Radiation 34Albumin-Bound Paclitaxel 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Non-Small-Cell Lung × Ointments × Clear all
NCT01593995 2014-11-04

EGF Ointment for Erlotinib Skin Lesion

Dong-A University Hospital

Phase 2 Completed
52 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡